(605116)"Aurisco Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
Filed with SSE · Stock code 605116 · · 2 pages · Chinese
Summary by 6ix AI
It will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted online. Investors can submit questions in advance through the designated platform or via email.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Aurisco Pharmaceutical Co. Ltd. on 6ix
Story so far
Earlier from Aurisco Pharmaceutical
- (605116)"Aurisco Pharmaceutical Co., Ltd."Announcement on Conversion Results of Convertible Bonds and Share Changes
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Obtaining Notice of Approval for Drug Supplementary Application by a Wholly-owned Subsidiary
- Announcement on the Wholly-owned Subsidiary Passing the U.S. FDA On-Site Inspection
- Announcement on the Proposed Selection of the Company's Products in the 12th Batch of National Centralized Drug Procurement
Follow Aurisco Pharmaceutical into a list and get an email when it puts out news.
Follow Aurisco Pharmaceutical